XML 38 R24.htm IDEA: XBRL DOCUMENT v3.26.1
Share Repurchase Program
 12 Months Ended
Dec. 31, 2025
Equity [Abstract]  
Share Repurchase Program

Note 14 – Share Repurchase Program

 

In March 2022, the Company’s board of directors authorized a share repurchase program that would allow the Company to repurchase up to $30,000,000 of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. There were no shares repurchased under this program during the year ended December 31, 2025.